DMAC DiaMedica Therapeutics Inc

Price (delayed)

$3.44

Market cap

$130.6M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.56

Enterprise value

$128.88M

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing novel treatments to improve the lives of patients with neurological and chronic kidney diseases.

Highlights
DMAC's debt is down by 17% year-on-year and by 5% since the previous quarter
The company's EPS rose by 7% QoQ and by 5% YoY
The quick ratio has soared by 76% YoY but it has contracted by 6% from the previous quarter
DiaMedica Therapeutics's equity has soared by 72% YoY but it has decreased by 9% from the previous quarter
The net income has contracted by 25% YoY

Key stats

What are the main financial stats of DMAC
Market
Shares outstanding
37.96M
Market cap
$130.6M
Enterprise value
$128.88M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.82
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$19.23M
EBITDA
-$19.13M
Free cash flow
-$20.32M
Per share
EPS
-$0.56
Free cash flow per share
-$0.54
Book value per share
$1.22
Revenue per share
$0
TBVPS
$1.3
Balance sheet
Total assets
$49.26M
Total liabilities
$2.91M
Debt
$380,000
Equity
$46.35M
Working capital
$44.87M
Liquidity
Debt to equity
0.01
Current ratio
18.14
Quick ratio
17.93
Net debt/EBITDA
0.09
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-34.5%
Return on equity
-36.2%
Return on invested capital
-38.3%
Return on capital employed
-41.2%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DMAC stock price

How has the DiaMedica Therapeutics stock price performed over time
Intraday
-1.43%
1 week
1.47%
1 month
59.26%
1 year
-4.71%
YTD
21.13%
QTD
16.61%

Financial performance

How have DiaMedica Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$21.49M
Net income
-$19.27M
Gross margin
N/A
Net margin
N/A
The operating income has contracted by 34% YoY
The net income has contracted by 25% YoY

Growth

What is DiaMedica Therapeutics's growth rate over time

Valuation

What is DiaMedica Therapeutics stock price valuation
P/E
N/A
P/B
2.82
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 7% QoQ and by 5% YoY
DiaMedica Therapeutics's equity has soared by 72% YoY but it has decreased by 9% from the previous quarter
The stock's price to book (P/B) is 43% more than its last 4 quarters average of 2.0 but 13% less than its 5-year quarterly average of 3.3

Efficiency

How efficient is DiaMedica Therapeutics business performance
DiaMedica Therapeutics's return on invested capital has increased by 24% YoY and by 10% QoQ
DiaMedica Therapeutics's return on equity has increased by 22% YoY and by 9% QoQ
The return on assets is up by 21% year-on-year and by 8% since the previous quarter

Dividends

What is DMAC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DMAC.

Financial health

How did DiaMedica Therapeutics financials performed over time
The quick ratio has soared by 76% YoY but it has contracted by 6% from the previous quarter
The current ratio has soared by 72% YoY but it has decreased by 6% QoQ
DMAC's debt is 99% smaller than its equity
DiaMedica Therapeutics's equity has soared by 72% YoY but it has decreased by 9% from the previous quarter
DiaMedica Therapeutics's debt to equity has plunged by 50% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.